AU2021359493A1 - Crystal forms of glp-1r agonists and uses thereof - Google Patents
Crystal forms of glp-1r agonists and uses thereof Download PDFInfo
- Publication number
- AU2021359493A1 AU2021359493A1 AU2021359493A AU2021359493A AU2021359493A1 AU 2021359493 A1 AU2021359493 A1 AU 2021359493A1 AU 2021359493 A AU2021359493 A AU 2021359493A AU 2021359493 A AU2021359493 A AU 2021359493A AU 2021359493 A1 AU2021359493 A1 AU 2021359493A1
- Authority
- AU
- Australia
- Prior art keywords
- crystalline form
- disease
- compound
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020120814 | 2020-10-14 | ||
| CNPCT/CN2020/120814 | 2020-10-14 | ||
| PCT/CN2021/123387 WO2022078352A1 (en) | 2020-10-14 | 2021-10-13 | Crystal forms of glp-1r agonists and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021359493A1 true AU2021359493A1 (en) | 2023-06-15 |
| AU2021359493A9 AU2021359493A9 (en) | 2025-01-09 |
Family
ID=78401981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021359493A Pending AU2021359493A1 (en) | 2020-10-14 | 2021-10-13 | Crystal forms of glp-1r agonists and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12516041B2 (https=) |
| EP (1) | EP4228753B1 (https=) |
| JP (1) | JP7769695B2 (https=) |
| CN (1) | CN116710446B (https=) |
| AU (1) | AU2021359493A1 (https=) |
| CA (1) | CA3195264A1 (https=) |
| ES (1) | ES3041328T3 (https=) |
| TW (1) | TWI912388B (https=) |
| WO (1) | WO2022078352A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114761395B (zh) * | 2019-12-02 | 2024-11-15 | 现代药品株式会社 | Glp-1受体激动剂 |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| CN117362282B (zh) * | 2022-07-07 | 2026-04-21 | 杭州德睿智药科技有限公司 | Glp-1r激动剂的盐及其制备方法和应用 |
| US20260028332A1 (en) * | 2022-07-18 | 2026-01-29 | Mindrank Therapeutics (Suzhou) New Drug Research And Development Co., Ltd | Polymorphic form of glp-1r agonist, preparation method therefor and use thereof |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EA018225B1 (ru) | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| AR083878A1 (es) * | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| DK3806855T5 (da) * | 2018-06-15 | 2023-05-22 | Pfizer | GLP-1-receptoragonister og anvendelser deraf |
| MA54555A (fr) * | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| EP3953344A4 (en) * | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | GLP-IR AGONISTS AND THEIR USES |
-
2021
- 2021-10-13 CN CN202180082321.9A patent/CN116710446B/zh active Active
- 2021-10-13 US US18/031,380 patent/US12516041B2/en active Active
- 2021-10-13 JP JP2023523059A patent/JP7769695B2/ja active Active
- 2021-10-13 EP EP21798552.2A patent/EP4228753B1/en active Active
- 2021-10-13 CA CA3195264A patent/CA3195264A1/en active Pending
- 2021-10-13 TW TW110138006A patent/TWI912388B/zh active
- 2021-10-13 ES ES21798552T patent/ES3041328T3/es active Active
- 2021-10-13 WO PCT/CN2021/123387 patent/WO2022078352A1/en not_active Ceased
- 2021-10-13 AU AU2021359493A patent/AU2021359493A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7769695B2 (ja) | 2025-11-13 |
| CN116710446B (zh) | 2024-10-18 |
| ES3041328T3 (en) | 2025-11-11 |
| TW202227421A (zh) | 2022-07-16 |
| EP4228753B1 (en) | 2025-07-30 |
| EP4228753C0 (en) | 2025-07-30 |
| TWI912388B (zh) | 2026-01-21 |
| WO2022078352A1 (en) | 2022-04-21 |
| EP4228753A1 (en) | 2023-08-23 |
| CA3195264A1 (en) | 2022-04-21 |
| US20230382899A1 (en) | 2023-11-30 |
| JP2023546125A (ja) | 2023-11-01 |
| US12516041B2 (en) | 2026-01-06 |
| AU2021359493A9 (en) | 2025-01-09 |
| CN116710446A (zh) | 2023-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4157832B1 (en) | Salt and crystal forms of glp-1r agonists and uses thereof | |
| US12516041B2 (en) | Crystal forms of GLP-1R agonists and uses thereof | |
| TWI809334B (zh) | ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式 | |
| CN112533674B (zh) | Glp-1受体激动剂及其用途 | |
| TW202214622A (zh) | Ｇｌｐ－１ｒ促效劑及其用途 | |
| US20250129057A1 (en) | Solid Forms of 2-[(4-{6-[(4-Cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt | |
| AU2023224854A1 (en) | Compounds as glp-1r agonists | |
| CN118401519A (zh) | 作为glp-1r激动剂的化合物 | |
| HK40089377A (en) | Crystal forms of glp-1r agonists and uses thereof | |
| HK40089377B (en) | Crystal forms of glp-1r agonists and uses thereof | |
| HK40087545A (en) | Salt and crystal forms of glp-1r agonists and uses thereof | |
| HK40087545B (en) | Salt and crystal forms of glp-1r agonists and uses thereof | |
| TWI913272B (zh) | Ｇｌｐ-１ｒ促效劑之鹽和晶型及其用途 | |
| CN104926706B (zh) | 六氢并环戊二烯衍生物的盐及其制备方法和应用 | |
| HK40082417A (en) | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |